2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.09 Saini

PP01.09 Saini - Abstract

Pdf Summary

A study investigated factors affecting responses to PD-(L)1 blockade in lung cancer patients with STK11 mutations. While STK11 mutations are often linked to resistance to immunotherapy, a portion of these patients still respond to treatment. Data from 892 patients showed that 15.9% had STK11 mutations, with 19.7% responding to immunotherapy. High PD-L1 expression (50%) was associated with better response rates and longer survival. Patients with high tumor mutational burden (TMB) also showed improved outcomes. Concurrent KRAS mutations in STK11MUT NSCLCs were linked to poorer responses. Different mutation subtypes and locations within STK11 were found to impact treatment efficacy. Patients with mutations in early exons 1-2 had worse survival compared to those with mutations in late exons 9-10. The study highlights the importance of considering specific genomic factors, such as PD-L1 expression and TMB, in determining the potential benefits of immunotherapy for patients with STK11MUT NSCLC.

Keywords

PD-(L)1 blockade

lung cancer

STK11 mutations

immunotherapy

PD-L1 expression

tumor mutational burden

KRAS mutations

genomic factors

NSCLC

treatment efficacy